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Bone marrow failureDefects in genes encoding ribosomal proteins cause Diamond Blackfan Anemia (DBA), a red cell aplasia often as-
sociated with physical abnormalities. Other bone marrow failure syndromes have been attributed to defects in
ribosomal components but the link between erythropoiesis and the ribosome remains to be fully defined. Several
lines of evidence suggest that defects in ribosome synthesis lead to “ribosomal stress” with p53 activation and
either cell cycle arrest or induction of apoptosis. Pathways independent of p53 have also been proposed to
play a role in DBA pathogenesis.
We took an unbiased approach to identify p53-independent pathways activated by defects in ribosome synthesis
by analyzing global gene expression in various cellular models of DBA. Ranking-Principal Component Analysis
(Ranking-PCA) was applied to the identified datasets to determine whether there are common sets of genes
whose expression is altered in these different cellular models. We observed consistent changes in the expression
of genes involved in cellular amino acidmetabolic process, negative regulation of cell proliferation and cell redox
homeostasis.
These data indicate that cells respond to defects in ribosome synthesis by changing the level of expression
of a limited subset of genes involved in critical cellular processes. Moreover, our data support a role for p53-
independent pathways in the pathophysiology of DBA.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Mutations in genes encoding ribosomal proteins result in Diamond
Blackfan Anemia (DBA), a bonemarrow failure syndrome characterized
by pure erythroid aplasia (Draptchinskaia et al., 1999; Vlachos et al.,
2008). In addition to bone marrow failure, malformations are observed
in approximately one third of the patients. DBA is inherited with an au-
tosomal dominant pattern and results fromhaploinsufficiency for singlebosomal protein; RS, ribosomal
mponent; GO, gene ontology.
ciences, University of Eastern
zani).
. This is an open access article underribosomal proteins (RPs). To date eleven genes encoding ribosomal pro-
teins have been foundmutated in DBA patients, i.e. RPS19, RPS24, RPS17,
RPL5, RPL11, RPS7, RPL35A, RPS26, RPS10, RPL26, and RPL15 (Boria et al.,
2010; Draptchinskaia et al., 1999; Gazda et al., 2012; Landowski et al.,
2013; Quarello et al., 2010).
In addition to DBA several other ribosomopathies have been de-
scribed (Narla and Ebert, 2010). Many of these are bonemarrow failure
syndromes but other ribosomopathieswhere hematopoiesis is unaffect-
ed have also been identified (Freed et al., 2010). TheDBA phenotype has
been ascribed to a peculiar sensitivity of the erythron and tissues of the
developing embryo to haploinsufficiency for ribosomal proteins. This
hypothesis is based on information obtained using both cellular models
and model organisms. Deficiencies in factors involved in ribosomethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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zebrafish and mouse (Danilova et al., 2008; Kongsuwan et al., 1985;
McGowan et al., 2008; Miller and Gurdon, 1970). These defects cause
the induction of a cellular stress response, called ribosomal (or nucleo-
lar) stress (RS) that results in activation of p53-dependent and indepen-
dent pathways, which block proliferation and/or induce apoptosis (Dutt
et al., 2011; Moniz et al., 2012; Torihara et al., 2011). Whereas pharma-
cological or genetic inhibition of p53 is able to attenuate phenotypes in
many of thesemodels, treatment based on p53 inhibition appears unre-
alistic in humans because of attendant cancer risks.
To shed light into pathways that are activated by ribosomal stress in
human cells expressing reduced levels of ribosomal proteins we have
studied the transcriptome of three different cellular models of DBA
looking for intersecting patterns of gene expression changes.
2. Design and methods
2.1. Cell cultures
Human erythroleukemia cell line TF1 (ATCC Number: CRL-2003)
was grown in RPMI 1640 medium supplemented with 10% FBS, 2 mM
L-glutamine, 100 UI/mL penicillin, 100 μg/mL streptomycin and 5 ng/mL
GM-CSF. TF1 cells expressing inducible shRNAs against RPS19 or a scram-
bled shRNA were provided by Dr. Stefan Karlsson (Miyake et al., 2005)
(shRNAs SCR, B and C). shRNA expression was induced by 0.5 μg/mL
doxycycline (DOX) for four days. TF1 cells for transduction were thawed
and maintained for minimum two passages before being transduced
with lentivirus prrl-shSCR or prrl-shRPL5A or prrl-shRPL11A (Moniz
et al., 2012) with an MOI of 10. Two days after transduction, Green Fluo-
rescent Protein (GFP) positive cells were sorted by flow cytometry and
cultured under the same conditions for four days.
For qRT-PCRvalidation andflowcytometric analysiswe also designed
and produced a third generation lentiviral vector (LV) system expressing
scrambled or RPS19 shRNA both of them co-expressing GFP under the
control of the human PGK promoter (Miyake et al., 2005) (shRNAs SCR
and C). LVs were obtained after transient transfection of 293T cells by
the calcium phosphate method (Taulli et al., 2005) with the packaging
plasmids (pMDLg/pRRE, pRSV-REV and pMD2-VSVG) and the transfer
vectors expressing either the scrambled or the RPS19 shRNA. TF1 cells
were transduced with MOI 10 the described LVs (Follenzi et al., 2000).
Transduction efficiency was evaluated after three days by GFP detection.
Cells were collected for analysis four days after transduction.
2.2. TP53 analysis
Genomic DNAwas isolated from TF1 cells using a QIAamp DNAMini
kit (Qiagen) according to themanufacturer's protocol. Primers were de-
signed to amplify exons 4–9 and their flanking regions. PCR was per-
formed using AmpliTaq Gold DNA Polymerase (Applied Biosystems)
and amplicons were sequenced in both directions using a Big Dye Ter-
minator® v1.1 cycle sequencing kit (Applied Biosystem) and an ABI
PRISM® 3100 genetic analyzer. Total RNA was isolated from TF1 cells
using a RNeasy Plus Mini kit (Qiagen) and reverse transcribed with a
High Capacity cDNA Reverse Transcription kit (Applied Biosystems).
TP53 was amplified from cDNA and sequenced. Sequencing of TP53
from primary CD34+ cells was performed in parallel as a wild type
control.
For the nuclear localization assay TF1 cells were lysed as previously
described (Andrews and Faller, 1991) and subjected to western blot
analysis.
2.3. Western blot
Cells were lysed in Lysis Buffer (50 mM Tris–HCl pH 8, 1 mM EDTA,
150 mMNaCl, 0.5% NP-40) supplemented with protease inhibitors. Cell
debris was removed by centrifugation at 13,000 g for 10 min and thesupernatant was collected. Proteins were separated on 12% SDS–PAGE,
transferred on nitrocellulose membrane and incubated with antibodies
specific for RPS19 (Abnova), RPL5 (Abcam), RPL11 (Invitrogen), β-actin
(Sigma), p53, nucleolin and GAPDH (Santa Cruz Biotechnology). Detec-
tion of immunoblotswas carried out withWestern Lightning® Plus-ECL
(PerkinElmer). Downregulation or overexpression of the proteins of
interest was estimated after normalization to the intensity of GAPDH
or β-actin.
2.4. Flow cytometry
Analysis of maturation markers was performed on TF1 cells four
days after transduction with SCR or RPS19 shRNAs. 5 × 104 cells were
incubated for 15 min with PE-conjugated antibodies specific for
CD117 (c-KIT), CD34, CD71 and CD235a (glycophorin A). Cells
were then washed with PBS and examined using a flow cytometer
(FACSCalibur, Becton-Dickinson). Cell cycle analysis was performed
using propidium iodide (PI) staining. Briefly, cells were fixed, treated
with RNase A and stained with PI 40 μg/mL, then subjected to flow
cytometry analysis.
2.5. RNA isolation and microarray processing
Total RNA formicroarray analysiswas isolatedusing either a TRIzol®
reagent (Invitrogen) or a RNeasy PlusMini kit (Qiagen) according to the
protocols supplied by themanufacturers. RNA quantification, quality as-
sessment and labeling were performed as described in Avondo et al.
(2009). Labeled cRNA was hybridized on Affymetrix GeneChip Human
Genome U133A 2.0 Arrays. Microarray processing and data analysis
were performed as described by Avondo et al. (2009).
2.6. Ranking-Principal Component Analysis (Ranking-PCA)
PCA (Massart et al., 1988, 1998) is amultivariate pattern recognition
method that allows the representation of the original dataset in a new
reference system characterized by new variables called principal com-
ponents (PCs). By the use of a restricted number of significant PCs, ex-
perimental noise and random variations can be eliminated. PCA is
exploited in Ranking-PCA (Marengo et al., 2010; Polati et al., 2012;
Robotti et al., 2011) to select themost discriminating variables (i.e. can-
didate biomarkers) between two groups of samples (e.g. control vs.
pathological) and sort them according to their decreasing discrimina-
tion ability. Here, Ranking-PCA was applied by calculating PCs in
leave-one-out (LOO) cross-validation. The analysis we performed
aimed to identify the transcriptome abnormalities found in human
TF1 cells with a defect of RPS19, RPL5 or RPL11.
The dataset consisted of measurements from two sets of
experiments:
- TF1 cell lines with downregulation of RPS19 (labeled S19 in Fig. 1)
and their SCR controls (labeled CS);
- TF1 cell lines downregulated for RPL5 and RPL11 (labeled L5 and L11
respectively) and their scrambled controls (labeled CL).
Since the datasetswere not directly comparable, theywere indepen-
dently mean centered (i.e. the average value of each variable is
subtracted from each sample for each dataset separately). Then,
Ranking-PCA was applied to the TF1 dataset consisting in 17 samples
(7 control and 10 pathological) described by 10,194 variables
(probes). Only the first PC was selected and provided the correct classi-
fication of all the samples, as assessed by calculation of the percent non-
error-rate (NER%), defined as the percentage of correct assignments
(NER% = 100%).
The performance of Ranking-PCA was compared to other classifica-
tion tools as Partial Least Squares-Discriminant Analysis (PLS-DA)
(Marengo et al., 2008) obtaining similar classification performances
Fig. 1. p53 in TF1 cells. A. TF1 cells do not present thewild type form of p53. Sequencing of genomic DNA showed twomutations in trans: one leads to the skipping of exon 7 and nonsense
mediatedmRNAdecay (NMD), the other induces frameshiftwithoutNMDandwas also detected by cDNA sequencing, as shown in the electropherogram. The aberrant transcript gives rise
to amutant protein that carries 93 incorrect amino acids at the C-terminus. Electropherogram of p53 from CD34+ primary cells and a schematic representation of p53 protein domains are
shown as awild type control. B. Immunoblotting performedwith an antibody against theN-terminal region of p53 reveals a smaller protein in TF1 cells than the full-length p53 expressed
by CD34+ cells.
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ranked according to their decreasing discriminant ability.
2.7. Quantitative RT-PCR
For qRT-PCR analysis total RNA was isolated using TRIzol® reagent.
cDNAwas synthesized using theHigh Capacity cDNAReverse Transcrip-
tion Kit (Applied Biosystems). Quantitative PCRwas performed with an
Abi Prism 7000 instrument (Applied Biosystems) using Taqman® Gene
Expression Assays (Applied Biosystems). PCR reactionswere run in trip-
licate. Ct values were normalized to GAPDH or β-actin, used as endoge-
nous controls, and expression levels were calculated with the ddCt
method (Livak and Schmittgen, 2001). Fold changes in the expression
of the target gene were equivalent to 2−ddCt. Fold change data are pre-
sented as mean ± SD. Data were analyzed with Student's t-test.
3. Results
3.1. Characterization of TF1 cell lines
RPS19-silenced TF1 cells have been widely employed to investigate
DBA pathophysiology (Badhai et al., 2009; Flygare et al., 2007; Miyake
et al., 2005, 2008). Using this cell model it was demonstrated for the
first time that human RPS19 is required for the maturation of 40S ribo-
somal subunits (Flygare et al., 2007). When RPS19-deficient TF1 cells
were treated with erythropoietin (EPO), significant suppression of ery-
throid differentiation, cell growth, and colony formation was observed(Miyake et al., 2005), along with the increase of apoptotic cells
(Miyake et al., 2008). These previous studies did not ascertain the status
of p53, whereas more recent investigations have pointed out that ribo-
somal stress activates both p53 dependent and independent pathways.
To address this issue we sequenced the TP53 gene in both parental and
RPS19 downregulated TF1 cell lines (Miyake et al., 2005). Sequencing of
genomic DNA showed two mutations in trans. On one allele, mutation
c.673-2ANG in the acceptor splice site of exon 7 is expected to lead to
the skipping of this exon and to nonsense mediated mRNA decay
(NMD, Fig. 1A), as confirmed by the absence of this transcript in cDNA
sequencing analysis (data not shown).
On the other allele, we detected mutation c.752delT, already de-
scribed by Urashima et al. (1998). We found that this mutation induces
frameshiftwithout NMD, since the stop codon of the new reading frame
is located in proximity of the last splicing site. This mutation was also
detected in p53 mRNA expressed by TF1 cells, as shown by cDNA se-
quencing (Fig. 1A). The aberrant transcript gives rise to a protein with
93 incorrect amino acids at the C-terminus and with a predicted size
of approximately 38 kDa (Fig. 1A). Accordingly, immunoblotting per-
formed with an antibody against the N-terminal region of p53 revealed
a smaller protein in TF1 cells than the full-length p53 expressed by
CD34+ cells (Fig. 1B). This protein lacks the nuclear localization signal
and part of the DNA binding domain, therefore it accumulates in the cy-
toplasm (Fig. S1) and is presumably inactive. The presence of null muta-
tions on both alleles of p53 makes TF1 cells a suitable model for the
investigation of p53-independent pathways activated by ribosomal
stress.
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We then investigated howRPS19 downregulation affected prolifera-
tion, apoptosis and maturation in TF1 cells cultured without EPO. Cells
expressing shRNA against RPS19 were examined after four days of
DOX treatment and compared to a scrambled (SCR) control. The level
of RPS19 protein was reduced to about 50% (Fig. 2A), thus mimicking
RP haploinsufficiency showed by DBA patients, who always carry the
deleteriousmutation in heterozygosity.We observed a slight, not signif-
icant decrease in proliferation (Fig. 2B).
Propidium iodide staining revealed a significant increase in the
subG1 population which includes late-stage apoptotic and necrotic
cells. Among viable cells, a large proportion of RPS19 silenced cells
were in G0/G1 phase, whereas the percentage of cells in G2/M phase de-
creased about 1.7 fold compared to SCR control (Fig. 2C).
We then characterized the phenotypic expression of surfacemarkers
by flow cytometry. TF1 cells were transduced with a lentivirus express-
ing SCR or RPS19 shRNAs and GFP as a reporter gene. The transduction
efficiency was higher than 97% (Fig. S2A). In this model, constitutively
expressing shRNAs, RPS19 downregulation, as well as its effects on pro-
liferation and cell cycle, was very similar to the DOX-inducible model
(data not shown). The proportion of cells positive for two early hemato-
poietic markers, c-KIT and CD34, and for two markers specific forFig. 2. RPS19 silencing in TF1 cells. A. Western blot showing the downregulation of RPS19 pro
densitometry analysis, performed on three replicates, shows a statistically significant downre
days. C. Cell cycle analysis by flow cytometry of TF1 cells treated with DOX for four days an
phase on total cells and the percentage of cells in G0/G1 and G2/M phase on viable cells, as theerythroid differentiation, CD71 and glycophorin A, was unchanged
(Fig. S2B).
3.3. Gene expression profiling of cells with RP deficiency
To identify p53-independent pathways activated by a RP defect, we
used three TF1 cell lines expressing shRNAs against RPS19, RPL5 or
RPL11, the three most frequently mutated DBA genes. The downregula-
tion of the respective ribosomal proteins was assessed by western blot-
ting (Figs. 2A, S3). The observed downregulation of RPL5was about 40%
and that of RPL11was about 70%, as comparedwith scrambled controls.
We analyzed whole genome expression profiles of the three TF1 cell
lines downregulated for RPS19, RPL5 or RPL11 (named hereafter TF1
shRPS19, TF1 shRPL5, TF1 shRPL11) as compared to SCR controls. The
expression study was performed using Affymetrix GeneChip Human
Genome U133A 2.0 Arrays which allow the screening of 18,400
transcripts. Each dataset showed a decrease in the transcript corre-
sponding to the downregulated RP (fold change RPS19: 0.12; RPL5:
0.26; RPL11: 0.11).
In order to identify the transcriptional signature of RP deficiency in
p53-deficient cells we intersected the three TF1 cell lines downregulat-
ed for RPS19, RPL5 and RPL11 using Ranking-PCA. Ranking-PCA is a sta-
tistical method that can select and sort the most discriminatingtein in TF1 cells, compared to scrambled controls, after four days of DOX treatment. The
gulation of RPS19. *p value b0.05. B. Growth curve of TF1 cells treated with DOX for four
d stained with propidium iodide. The bar graphs show the percentage of cells in subG1
mean of three replicates. Standard deviation bars are shown. *p value b0.05.
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et al., 2011). Fig. 3 represents the results of PCA performed on the first
205 variables selected by Ranking-PCA. The first PC accounts for about
79% of the overall information. The selected variables are reported in
Table S1 according to the order in which they were included in the
Ranking-PCA model. It is important to note that the results obtained
by Ranking-PCA do not necessarily include all the genes that have the
highest fold change in RP-deficient cells as compared to their controls.
Instead the analysis is carried out to provide the set of dysregulated
genes common to the three TF1 cell lines silenced for RPS19, RPL5 or
RPL11: a gene is added only if it shows a similar dysregulation in all
datasets. Although PC2 is responsible for only about 4% of the total infor-
mation, it does reflect effects of the pathology since control and patho-
logical samples from the same cell line (TF1-S and TF1-L cell lines) lie at
opposite values along this PC. PC1 and PC2 together are able to clearly
distinguish the four groups of samples corresponding to two different
downregulation models (TF1-S is an inducible model, whereas L is a
constitutive downregulation model), both control and pathological,
and to RPs pertaining to different ribosome subunits.3.4. Biological processes altered in cells with RP deficiency
In order to systematically detect impaired biological processes
of these cells, we analyzed the genes included in the Ranking-PCA list
by employing the tool of gene annotation provided byDAVID (Database
for Annotation, Visualization and Integrated Discovery) at http://david.
abcc.ncifcrf.gov/. The results included classifications according to Gene
Ontology (GO) and PANTHER databases. GO categories for Biological
Processes showed an enrichment, among others, of genes involved in
cellular amino acid metabolic process, negative regulation of cell prolif-
eration, apoptosis and cell redox homeostasis (Table 1). The PANTHER
Biological Process annotation identified statistically significant over-
representation of genes involved in hematopoiesis and in amino acid
and steroid metabolism (Table 2).
Two genes stood out whose expression was increased in this analy-
sis, EPOR and TFRC, whereas another noteworthy gene, SOD2, displayed
reduced expression (Table S1).
Among the differentially expressed genes, there were only four
genes whose transcription could be activated by p53 (Riley et al.,
2008): APAF1, FDXR, SCD and PYCARD. The first three genes were
downregulated, whereas the proapoptotic gene PYCARD showed aFig. 3. PCAon RP deficient TF1 cells. Score plot of thefirst two PCs calculated on the dataset
containing TF1 cell lines downregulated for RPS19, RPL5 and RPL11. Samples are separated
along PC1 in controls (positive scores; empty circles) and pathological (negative scores;
full circles). Labels: S19 = TF1 downregulated for RPS19; CS = scrambled controls for
RPS19; L5 and L11= TF1 downregulated for RPL5 and RPL11; CL= scrambled controls
for RPL5 and RPL11.higher level in RPS19 silenced TF1 cells. As expected, the vast majority
of knownp53 targets (Riley et al., 2008) did not show an altered expres-
sion in RP depleted TF1 cells. Our data suggest that the increased ex-
pression of PYCARD may be mediated by p53 independent pathways.
3.5. Quantitative RT-PCR validation of microarray data
In order to corroborate the microarray gene expression results, we
selected eight genes among the top genes of the Ranking-PCA list or
among those highlighted by the PANTHER analysis. Real-time RT-PCR
was performed on the same RNA samples used for microarray analysis
(TF1 shRPL5, TF1 shRPL11) or on different samples with a similar level
of RP downregulation (TF1 shRPS19, both DOX-inducible model and
transduced cells constitutively expressing shRNAs). The expression
level of FTH1 and PLIN2 (up-regulated in RP defective cells) and
SLC38A1, TOM1L1, ASNS, CTH, GARS and PHGDH (down-regulated in
RP defective cells) was tested. All genes were found concordantly dys-
regulated in RP depleted cells compared to scrambled controls (Fig. 4).
These data imply that the expression patterns detected by microarray
analysis are in good agreement with those detected by qRT-PCR and
validate our conclusions.
4. Discussion
Many lines of evidence have underscored the pivotal role of p53 ac-
tivation in the induction of cell death and proliferation block in cells and
organisms subjected to ribosomal stress (Danilova et al., 2008; Dutt
et al., 2011; Ellis and Gleizes, 2011;McGowan et al., 2008). The decrease
in p53 activity by geneticmeans or using chemical inhibitors has proven
useful to attenuate the proapoptotic phenotype of these models. How-
ever, p53 inhibitors cannot be used in the therapy of patients with
DBA because they would drastically increase their cancer risk. The
identification of p53-independent pathways that are induced by
ribosomal stress may suggest new druggable steps that could bemodu-
lated to reduce the phenotypic consequences of ribosomal protein
haploinsufficiency.
The aim of our work was to identify the p53-independent cellular
processes that are altered during ribosomal stress due to deficiency of
DBA RPs. To this aim we have used human TF1 cell lines that were si-
lenced for the three RPs that are most commonly mutated in DBA pa-
tients, i.e. RPS19, RPL5 or RPL11. In fact, TF1 cells carry deleterious
mutations on both p53 alleles, which abolish p53 function, as shown
by sequencing and functional studies.
To search for impaired processes we have intercepted the
transcriptomes of the three TF1 cell lines using Ranking-PCA. We iden-
tified genes involved in cell proliferation and apoptosis, in agreement
with a previous study that showed abnormal levels of apoptosis related
proteins in TF1 cells downregulated for RPS19 (Miyake et al., 2008).We
detected the upregulation of PYCARD, a transcript encoding a
proapoptotic protein that triggers the activation of caspases (Ohtsuka
et al., 2004). Overexpression of Pycard in mouse inhibits the prolifera-
tion of erythroid cells, promotes their apoptosis, and interferes with
their terminal differentiation (Hu et al., 2011). Abnormal expression of
genes related to apoptosis was also reported in bone marrow CD34+
cells isolated from three DBA patients with mutations in RPS19 and in
remission from the disease (Gazda et al., 2006), and in a previous
study by our group focused on unraveling the gene expression alter-
ations in fibroblasts isolated from DBA patients with RPS19 mutations
(Avondo et al., 2009).
Moreover, a large cluster of significantly underexpressed RPs was
described in these two reports (Avondo et al., 2009; Gazda et al.,
2006). On the contrary, both the present study and a previous one
which examined RPS19-deficient TF1 cells showed normal levels of RP
mRNAs, with the exception of RPL3 (Badhai et al., 2009, Table S1).
This lack of congruence might be explained by the presence or absence
of wt p53 in primary cells and TF1 model, respectively. In fact, it is
Table 1
Genes included in the PC1 were annotated using Gene Ontology biological process.
Term Count p value Genes
GO:0008610 — lipid biosynthetic process 19 4.12E−08 FCER1A, EBP, SPTLC2, SCD, HMGCS1, FDXR, LTC4S, SC4MOL, FDFT1, FAR2, PIGK, PIGF, LPCAT1,
SH3GLB1, DHCR7, PBX1, LTA4H, SC5DL, NSDHL
GO:0016053 — organic acid biosynthetic process 12 1.99E−06 FCER1A, C8ORF62, SCD, ASNS, LTC4S, SC4MOL, CTH, GOT1, SH3GLB1, PHGDH, LTA4H, PSAT1,
SC5DL
GO:0016126 — sterol biosynthetic process 7 2.84E−06 EBP, DHCR7, HMGCS1, SC5DL, FDFT1, SC4MOL, NSDHL
GO:0006694 — steroid biosynthetic process 9 6.53E−06 EBP, DHCR7, HMGCS1, FDXR, PBX1, SC5DL, FDFT1, SC4MOL, NSDHL
GO:0043436 — oxoacid metabolic process 21 7.41E−06 FCER1A, C8ORF62, SCD, CS, GARS, EPRS, ASNS, LTC4S, PCK2, SLC7A5, SC4MOL, MTHFD2, CTH,
GOT1, SH3GLB1, GFPT1, PHGDH, LTA4H, DDAH2, PSAT1, SC5DL, ALDH9A1
GO:0044106 — cellular amine metabolic process 14 5.98E−05 C8ORF62, GARS, EPRS, ASNS, SLC7A5, CTH, GOT1, GFPT1, PHGDH, SMOX, PAFAH1B1, AMD1,
PSAT1, DDAH2, ALDH9A1
GO:0044255 — cellular lipid metabolic process 16 0.0013 FCER1A, SPTLC2, SCD, HMGCS1, PIP5K1B, LTC4S, SC4MOL, FDFT1, PIGK, PIGF, LPCAT1,
SH3GLB1, LTA4H, PAFAH1B1, SC5DL, NR1H3
GO:0006520 — cellular amino acid metabolic process 10 0.0014 C8ORF62, CTH, GOT1, GFPT1, GARS, PHGDH, EPRS, ASNS, PSAT1, DDAH2, SLC7A5
GO:0006633 — fatty acid biosynthetic process 6 0.0023 FCER1A, SCD, LTA4H, LTC4S, SC5DL, SC4MOL
GO:0009309 — amine biosynthetic process 6 0.0026 C8ORF62, CTH, GOT1, PHGDH, ASNS, PSAT1, AMD1
GO:0008202 — steroid metabolic process 9 0.0026 EBP, DHCR7, HMGCS1, FDXR, PBX1, SC5DL, FDFT1, SC4MOL, NSDHL
GO:0006575 — cellular amino acid derivative metabolic process 8 0.0034 CTH, PHGDH, PAFAH1B1, SMOX, AMD1, ALDH9A1, SOD2, GLRX2
GO:0008203 — cholesterol metabolic process 6 0.0044 EBP, DHCR7, HMGCS1, FDXR, FDFT1, NSDHL
GO:0010243 — response to organic nitrogen 5 0.0063 ALDOC, HMGCS1, ASNS, PPP3CA, DDIT3
GO:0019725 — cellular homeostasis 13 0.0086 CLNS1A, FTH1, DDIT3, SOD2, GLRX2, LOC100130902, TFRC, FTHL3, FTHL16, EPOR, TXNRD1,
PPP3CA, SH3BGRL3, SLC39A4, EIF2B4, FTHL20, ADD1
GO:0008285 — negative regulation of cell proliferation 11 0.0099 CEBPA, LST1, FTH1, SOD2, MAGED1, CTH, CDKN2A, FTHL3, BTG3, MYO16, FTHL16, ASPH,
EMP3, FTHL20
GO:0006915 — apoptosis 15 0.0109 DPF2, ALDOC, LGALS1, SOD2, TRADD, GLRX2, MAGED1, CDKN2A, SHARPIN, SH3GLB1, BRE,
PYCARD, AVEN, APAF1, TRAF3
GO:0006259 — DNA metabolic process 13 0.0156 GLRX2, MCM6, SOD2, TFAM, CDKN2A, CSNK1D, RRM1, MUS81, BRE, APAF1, OGG1, TRIP13,
RBMS1
GO:0043450 — alkene biosynthetic process 3 0.0204 FCER1A, LTA4H, LTC4S
GO:0006644 — phospholipid metabolic process 7 0.0241 PIGK, PIGF, LPCAT1, SH3GLB1, PIP5K1B, PAFAH1B1, FDFT1
GO:0006691 — leukotriene metabolic process 3 0.0269 FCER1A, LTA4H, LTC4S
GO:0006732 — coenzyme metabolic process 6 0.0338 MTHFD2, CTH, PANK3, CS, SOD2, GLRX2
GO:0021570 — rhombomere 4 development 2 0.0347 HOXA1, HOXB2
GO:0006461 — protein complex assembly 12 0.0348 TFAM, CTH, TSPAN4, ALDOC, IRF7, RRM1, EPRS, TUBA4A, HSPA4, WIPF1, SURF1, SOD2
GO:0030262 — apoptotic nuclear changes 3 0.0367 CDKN2A, SHARPIN, APAF1
GO:0044271 — nitrogen compound biosynthetic process 9 0.0371 CEBPA, C8ORF62, CTH, GOT1, RRM1, PHGDH, ASNS, PSAT1, DDAH2, AMD1
GO:0045454 — cell redox homeostasis 4 0.0374 LOC100130902, TXNRD1, SH3BGRL3, DDIT3, GLRX2
GO:0046486 — glycerolipid metabolic process 6 0.0416 PIGK, PIGF, SH3GLB1, PIP5K1B, PAFAH1B1, NR1H3
GO:0006749 — glutathione metabolic process 3 0.0421 CTH, SOD2, GLRX2
GO:0021610 — facial nerve morphogenesis 2 0.0460 HOXA1, HOXB2
GO:0021569 — rhombomere 3 development 2 0.0460 HOXA1, HOXB2
GO:0021604 — cranial nerve structural organization 2 0.0460 HOXA1, HOXB2
GO:0021612 — facial nerve structural organization 2 0.0460 HOXA1, HOXB2
GO:0009888 — tissue development 14 0.0479 S100A4, TRIM15, LOC100130902, CDKN2A, HOXB2, SHARPIN, GFPT1, SEMA3C, EPOR,
TXNRD1, PBX1, APAF1, CA2, PPP3CA, NSDHL
GO:0006650 — glycerophospholipid metabolic process 5 0.0496 PIGK, PIGF, SH3GLB1, PIP5K1B, PAFAH1B1
287A. Aspesi et al. / Gene 545 (2014) 282–289known that p53 can inhibit mTORC1 (Hasty et al., 2013), which medi-
ates the transcription of RP genes (Xiao and Grove, 2009).
The expression of several genes involved in erythroid maturation
is increased, in particular, erythropoietin receptor (EPOR), transferrin
receptor (TFRC), CDKN2A, that encodes for p16, whose transcriptional
upregulation in progenitor cells promotes differentiation (Minami
et al., 2003), and HOXB2, a target of the erythroid transcription
factor GATA1 (Vieille-Grosjean andHuber, 1995). However, maturation
is not altered in these cells in our experimental conditions, as
shown by the immunophenotypic analysis of RPS19 downregulated
TF1 cells.
Interestingly, enrichment of genes involved in hematopoiesis and
cell redox homeostasis was observed. Our study shows a downregula-
tion of certain genes that participate in the protection against oxidativeTable 2
Genes included in the PC1 were annotated using Panther.
Term Count p valu
BP00297: other steroid metabolism 3 0.0048
BP00026: cholesterol metabolism 5 0.0054
BP00284: hematopoiesis 5 0.0063
BP00013: amino acid metabolism 8 0.0085
BP00014: amino acid biosynthesis 4 0.0122
BP00295: steroid metabolism 6 0.0314stress, in particular superoxide dismutase 2 (SOD2) and thioredoxin re-
ductase 1 (TXNRD1) in cells depleted of RPs. A reduced expression of
SOD2 was observed also in RPL11-deficient zebrafish (Danilova et al.,
2011). These results indicate that cells depleted of RPs may have an
enhanced sensitivity to oxidative stress. The same phenomenon has
been suggested for two other bone marrow failure syndromes, i.e.
Fanconi Anemia (FA) and Shwachman-Diamond Syndrome (SDS).
This sensitivity may lead to increased apoptosis and decreased cell
growth (Ambekar et al., 2010; Bogliolo et al., 2002; Mukhopadhyay
et al., 2006).
Finally, we found dysregulation of clusters of genes involved in
amino acid metabolism and lipid metabolism. Downregulation of
genes involved in biosynthetic processes has been reported also in
zebrafish with a RPL11 deficiency (Danilova et al., 2011).e Genes
SC5DL, FDFT1, SC4MOL
EBP, HMGCS1, FDFT1, SC4MOL, NSDHL
CEBPA, STAP1, EPOR, PBX1, TRIM15
C8ORF62, CTH, GOT1, SLC7A1, CS, PHGDH, ASNS, PSAT1, SLC7A5
C8ORF62, CS, PHGDH, ASNS, PSAT1
EBP, HMGCS1, SC5DL, FDFT1, SC4MOL, NSDHL
Fig. 4.Validation ofmicroarray results by qRT-PCR. Fold change of the expression of eight altered genes in RP depleted TF1 cells compared to scrambled controls (set equal to 1). Datawere
obtained by qRT-PCR measurement and normalized to GAPDH or β-actin levels. *p value b0.05, ○p b 0.01, ‡p b 0.001.
288 A. Aspesi et al. / Gene 545 (2014) 282–289All these data show that when a RP is defective there is a set of bio-
logical functions/molecular processes that are affected in different types
of human cells, either primary cells from DBA patients or experimental
models. The increased destruction of erythroid progenitors observed in
patients with DBA may be due to the cumulative effects of p53-
dependent and -independent pathways. Cells that undergo ribosomal
stress alter the expression profile of a set of genes, which are consistent
with the pro-apoptotic and hypo-proliferative phenotype. Further stud-
ies are needed to ascertain whether antioxidant treatment may relieve
the DBA phenotype in vitro.
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